NICE now backs Jardiance for Type II diabetes

The U.K.'s NICE issued a Jardiance empagliflozin ( BI-10773) from partners Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY)

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE